Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kong, Ling Lei ^a   Zhuang, Xiao Mei ^b   Yang, Hai Ying ^b   Yuan, Mei ^a   Xu, Liang ^a   Li, Hua ^a,b  

^a State Key Laboratory of Toxicology and Medical Countermeasures   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOPTOSIS REGULATORY PROTEIN; ASPARTATE AMINOTRANSFERASE; DIGOXIN; DITERPENE; EPOXIDE; IMMUNOLOGIC FACTOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; PHENANTHRENE DERIVATIVE; PROTEIN BINDING; QUINOLINE DERIVATIVE; SMALL INTERFERING RNA; TARIQUIDAR; TRIPTOLIDE;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; GENE SILENCING; GENETICS; MALE; METABOLISM; MOLECULAR DOCKING; OXIDATIVE STRESS; TOXIC HEPATITIS; TUMOR CELL LINE;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; ASPARTATE AMINOTRANSFERASES; CELL LINE, TUMOR; CHEMICAL AND DRUG INDUCED LIVER INJURY; DIGOXIN; DITERPENES; EPOXY COMPOUNDS; GENE KNOCKDOWN TECHNIQUES; IMMUNOLOGIC FACTORS; MALE; MICE, INBRED BALB C; MOLECULAR DOCKING SIMULATION; OXIDATIVE STRESS; P-GLYCOPROTEINS; PHENANTHRENES; PROTEIN BINDING; QUINOLINES; RNA, SMALL INTERFERING;

EID: 84934777263     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11747     Document Type: Article

References (51)

1. Li, J. et al. Comparison of toxic reaction of Tripterygium wilfordii multiglycoside in normal and adjuvant arthritic rats. J Ethnopharmacol. 135, 270-277 (2011
2. Zheng, Y., Zhang, W. J. &Wang, X. M. Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurosci Ther. 19, 76-82 (2013
3. Liu, Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 11, 377-383 (2011
4. Chen, B. J. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 42, 253-265 (2001
5. Chai, Z. et al. Experimental progress of liver toxicity of Tripterygium Wilfordii and its mechanism. Chinese J Experi Traditional Medical Formula. 7, 243-246 (2011
6. Li, X. J., Jiang, Z. Z. &Zhang, L. Y. Triptolide: Progress on research in pharmacodynamics and toxicology. J Ethnopharmacol. 155, 67-79 (2014
7. Wang, X., Xu, L. &Wang, M. Hepatotoxicity caused by commonly used Chinese medicinal herbs and compound preparation. J Capital Medical University. 28, 220-224 (2007
8. Xue, J., Jia, X. B., Tan, X. B. &Hao, K. Study on hepatotoxicity induced by Triptergium wilfordii and its thoughts of assessment based on ADME/Tox. Chinese Traditional Herbal Drugs. 4, 655-658 (2009
9. Shao, F. et al. Pharmacokinetic study of triptolide, a constituent of immunosuppressive chinese herb medicine, in rats. Biol Pharm Bull. 30, 702-707 (2007
10. Xue, M. et al. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats. Eur J Pharm Sci. 47, 713-717 (2012
11. Xue, X. et al. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett. 205, 47-54 (2011
12. Du, F., Liu, Z., Li, X. &Xing, J. Metabolic pathways leading to detoxification of triptolide, a major active component of the herbal medicine Tripterygium wilfordii. J Appl Toxicol. 34, 878-884 (2014
13. Yao, J. C. et al. Metabolism and enzyme kinetics of triptolide in rat liver microsomes. Chin Pharm. 21, 577-579 (2010
14. Liu, L. et al. Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology. 271, 57-63 (2010
15. Shen, G. et al. Role of CYP3A in regulating hepatic clearance and hepatotoxicity of triptolide in rat liver microsomes and sandwich-cultured hepatocytes. Food Chem Toxicol. 71, 90-96 (2014
16. Ye, X. et al. Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett. 192, 212-220 (2010
17. Liu, J., Zhou, X., Chen, X. Y. &Zhong, D. F. Excretion of [3H]triptolide and its metabolites in rats after oral administration. Acta Pharmacol Sin. 35, 549-554 (2014
18. Zhuang, X. M. et al. Assessment of the roles of P-glycoprotein and cytochrome P450 in triptolide-induced liver toxicity in sandwich-cultured rat hepatocyte model. Drug Metab Dispos. 41, 2158-2165 (2013
19. Giacomini, K. M. et al. Membrane transporters in drug development. Nat Rev Drug Discov. 9, 215-236 (2010
20. Lundquist, P. et al. Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition. Drug Metab Dispos. 42, 448-458 (2014
21. Hendrikx, J. J. et al. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer. 132, 2439-2447 (2013
22. Pal, D. &Mitra, A. K. MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci. 78, 2131-2145 (2006
23. Pal, D. &Mitra, A. K. MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 1, 323-339 (2006
24. Zhang, L., Zhang, Y. &Huang, S. M. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm. 6, 1766-1774 (2009
25. Food and Drug Administration. Guidance for Industry. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. (2012) Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm292362.pdf. (Accessed: 13th December 2013
26. Engels, J. W. Gene silencing by chemically modified siRNAs. N Biotechnol. 30, 302-307 (2013
27. Tian, X., Zhang, P., Zamek-Gliszczynski, M. J. &Brouwer, K. L. Knocking down transport: applications of RNA interference in the study of drug transport proteins. Drug Metab Rev. 37, 705-723 (2005
28. Yu, A. M. Small interfering RNA in drug metabolism and transport. Curr Drug Metab. 8, 700-708 (2007
29. Abbasi, M., Lavasanifar, A. &Uludag, H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev. 33, 33-53 (2013
30. Matsui, Y., Kobayashi, N., Nishikawa, M. &Takakura, Y. Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm Res. 22, 2091-2098 (2005
31. Patutina, O. A. et al. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer. 10, 204 (2010
32. Li, X. et al. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp. Toxicol Appl Pharmacol. 275, 163-175 (2014
33. Jara, G. E., Vera, D. M. &Pierini, A. B. Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. J Mol Graph Model. 46, 10-21 (2013
34. Mei, Z., Li, X., Wu, Q., Hu, S. &Yang, X. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacol Res. 51, 345-351 (2005
35. Fu, Q. et al. Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury. Fitoterapia. 82, 1241-1248 (2011
36. Yao, J. et al. Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells. Biol Pharm Bull. 31, 592-597 (2008
37. Del Rio, D., Stewart, A. J. &Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 15, 316-328 (2005
38. Pellegrini, M. &Strasser, A. A portrait of the Bcl-2 protein family: life, death, and the whole picture. J Clin Immunol. 19, 365-377 (1999
39. Ola, M. S., Nawaz, M. &Ahsan, H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 351, 41-58 (2011
40. Law, S. K. et al. Molecular analyses of the Chinese herb Leigongteng (Tripterygium wilfordii Hook.f.). Phytochemistry. 72, 21-26 (2011
41. Zhang, L., Zhang, Y. D., Zhao, P. &Huang, S. M. Predicting drug-drug interactions: an FDA perspective. AAPS J. 11, 300-306 (2009
42. Abraham, J. et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res. 15, 3574-3582 (2009
43. Patel, N. R., Rathi, A., Mongayt, D. &Torchilin V. P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm. 416, 296-299 (2011
44. Kuntner, C. et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET. Eur J Nucl Med Mol Imaging. 37, 942-953 (2010
45. Aller, S. G. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 323, 1718-1722 (2009
46. Cosconati, S. et al. Virtual Screening with AutoDock: Theory and Practice. Expert Opin Drug Discov. 5, 597-607 (2010
47. Seeliger, D. &de Groot, B. L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 24, 417-422 (2010
48. Fuest, C. et al. In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. Neurosci Lett. 464, 47-51 (2009
49. Honjo, K. et al. MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes. J Gene Med. 12, 219-227 (2010
50. Pichler, A., Zelcer, N., Prior, J. L., Kuil, A. J. &Piwnica-Worms, D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res. 11, 4487-4494 (2005
51. Fox, E. &Bates, S. E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 7, 447-459 (2007